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Background: The number of cancer survivors has increased as a result of significant
progress in prevention, diagnosis and treatment of malignant tumors and the incidence
of MPC in surviving cancer patients (p) is also rising. This study investigates the co-
occurrence of MPC among p diagnosed with lung cancer (LC).
Methods: Review of clinical data of all consecutive patients with histologically con-
firmed LC visited at our institution between October 2017 and January 2018.
Results:Out of 933 p, two primary cancers occurred in 115 cases (12%), including 25 p
(3%) with three primary cancers. Patients withMPCwere predominantly males (69%),
smokers (85%) and 20% had known family history. Median age at the first tumor was
61 years (44-85). LC occurred as first neoplasm in 21% of the cases, as subsequent neo-
plasm in 64% and as two consecutive primary neoplasm in 15%.Most common cancer
previous to LC diagnosis was colorectal in 23%, breast in 22%, prostate in 19%, head
and neck in 12% and bladder in 11%. Treatment received for first cancer included sur-
gery in 79%, chemotherapy in 50% and radiotherapy in 30%. Second tumor was pros-
tate in 22%, bladder in 22%, colorectal in 19%, breast in 19% and head and neck in 8%.
Surgery was performed in 66% of the cases with second cancer. Overall, median time
from diagnosis of first to second neoplasmwas 4 years (2.9 -5.2), without significant
differences if primary tumor was LC or another neoplasm (p¼ 0.39). Of note, 25% had
diagnosis of second primary cancer within 1 year. Smoking was significantly associated
with shorter time to diagnosis of a second neoplasm (3.4 years vs 4.7 years for non-
smokers, p¼ 0.03). With a median follow up of 2 years after diagnosis of second neo-
plasm, the 2-year survival rate was 93.7% (88.8-98.7%). Having a second cancer within
3 years significantly increased the risk of death (HR¼ 7.7, p¼ 0.02).
Conclusions: In our series, the frequency of the co-occurrence of MPC among LC p is
12%, indicating that surveillance strategies are recommended. Many p are treated with
curative intent. Smoking increased risk of second primary, and diagnosis within 3 years
of follow-up associates with poor outcome.
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Background: Tumor Treating Fields (TTFields) are an anti-mitotic, regional treatment
modality, using low intensity alternating electric fields delivered non-invasively to the
tumor using a portable, medical device. In vitro, humanmesothelioma cells were highly
susceptible to TTFields. TTFields have been shown to extend survival of patients with
glioblastoma when added to chemotherapy.
Methods: The trial accrued 80 patients with unresectable, untreated mesothelioma.
Patients were treated with continuous 150 kHz TTFields in combination with peme-
trexed and platinum. Inclusion criteria included ECOG 0-1 and at least one measurable
lesion according to modified RECIST. Patients were followed q3w (CT scan q6w) until
disease progression. The primary endpoint was overall survival (OS). This single arm
study assumed historical control with a median survival of 12.1 months (Vogelzang et
al. 2003). The sample size provided 80% power with a two-sided alpha of 0.05 to detect
an increase in median OS of 5.5 months.
Results:All patients had a minimum follow up of 12months. Median age was 67 (range
27-78), 84% were male and 56% smokers. 16% (13 patients) hadmetastatic disease and
44% (35 patients) had an ECOG PS of 1. 66% (53 patients) had epithelioid histology.
Compliance with TTFields was 68% (16.3 hours/day) during the first 3 months of ther-
apy. Median OS was 18.2 months (95%CI 12.1-25.8) compared to 12.1 months in his-
torical controls. Median PFS was 7.6 months (95%CI 6.7-8.6) compared to 5.7 months
in historical controls. Partial responses were seen in 40.3% of patients and clinical bene-
fit (PRþSD) was seen in 97.2% of patients. No device-related serious adverse events
(AEs) were reported. Expected TTFields-related dermatitis was reported in 46% (37
patients). Only 4 patients (5%) had grade 3 dermatitis.
Conclusions: The study met its primary endpoint of significant extension of survival
for previously untreatedmesothelioma patients. Secondary efficacy endpoints were
also improved compared to historical control. The study demonstrated no safety con-
cerns for the combination of TTFields to the thorax with chemotherapy. These results
support the addition of TTFields to chemotherapy in the first-line treatment of malig-
nant pleural mesothelioma.
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Background:Malignant mesothelioma (MM) is an aggressive and fatal tumor, mainly
related to prolonged exposure to asbestos. MM can induce infiltration of immune cells
and immunity-mediated death. Tumormicroenvironment plays a major role in neo-
plastic progression, favoring tumor cell evasion from adaptive immunity and T-cell
checkpoint pathways. Expression of programmed death-ligand 1 (PD-L1) on tumor
cells and tumor-infiltrating lymphocytes (TILs) has been described in literature.
Cancer cells expressing PD-L1 increase apoptosis of antigen-specific human T-cell
clones and inhibit CD4þ and CD8þ T-cell activation, thus decreasing the immune
action on the tumor cells. Somemismatch repair–deficient tumors make them sensitive
to immune checkpoint blockade, because of the increased number of neoantigens
encoded by cancers, which enhances anti-tumor response.
Methods: The aim of this study is to analyze the expression of PD-L1 on both tumor
cells and TILs and to characterize TILs. Furthermore, MisMatchRepair (MMR) protein
expression was evaluated. Immunohistochemistry was applied using the automated
system BenchMark XT (VENTANA) for PD-L1 (DAKO, clone 22C3), CD4, CD8 and
MLH1,MSH2, MSH6, PMS2.
Results: 55 malignant mesotheliomas, 10 from women and 45 frommen, were
studied. The range of age was 43-88 years old. Tumors consisted of 44 epithelioid, 3
sarcomatoid, 7 biphasic and 1 desmoplastic. 51 were localized to pleura and 4 to peri-
toneum. 18 tumors were in stage I, 13 in stage II, 15 in stage III and 5 in stage IV. For 4
cases the stage was not evaluable. Our results showed expression of PD-L150% in
tumor cells in 9 cases (5 epithelioid, 2 sarcomatoid, 1 biphasic and 1 desmoplastic). In
two of these the positivity was observed both in tumor cells and in TILs. 15 tumors
were negative and 31 showed a positive staining1. A presence of TILs was observed
in 53 cases. A prevalence of CD4þ expression was highlighted in 45 cases. 6 of them
showed elevated expression of PD-L1 (50%). Alteration inMMR staining was not
found.
Conclusions:Our data underline the role of tumor immune microenvironment and its
characterization inMM and open the possibility to use combined therapies according
to different PD-L1 expression.
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